ConductScience.org, home

Paper8954169

Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.

Schwendener RA and 1 other. J Cancer Res Clin Oncol, 1996. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. Papers, record 8954169. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8954169

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
PubMed
Journal
J Cancer Res Clin Oncol
PubMed
Year
1996
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
1.76
iCite
Revised in PubMed
2025-07-19
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schwendener RAR A
2Schott HH

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antimetabolites, AntineoplasticMajor topic
CytarabineMajor topic
Leukemia L1210Major topic
Administration, Oral
Animals
Female
Infusions, Parenteral
Liposomes
Mice
Mice, Inbred Strains
Neoplasm Transplantation
Structure-Activity Relationship

Source PubMed

Download CSV of topics

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13719896Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3719896PubMed
27554036Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7554036PubMed
38836110Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.Anticancer Drug Des1996https://conductscience.org/library/papers/8836110PubMed
45289712Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.Clin Pharmacol Ther1971https://conductscience.org/library/papers/5289712PubMed
58576276Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8576276PubMed
67554040Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7554040PubMed
77577448Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine.Br J Cancer1995https://conductscience.org/library/papers/7577448PubMed
87596174Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.Leukemia1995https://conductscience.org/library/papers/7596174PubMed
97734320Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.Br J Cancer1995https://conductscience.org/library/papers/7734320PubMed
101749580Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.Oncology1991https://conductscience.org/library/papers/1749580PubMed
112507491Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.Jpn J Cancer Res1989https://conductscience.org/library/papers/2507491PubMed
123941019Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.Int J Cancer1986https://conductscience.org/library/papers/3941019PubMed
137791024Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes.J Pharm Pharmacol1995https://conductscience.org/library/papers/7791024PubMed
147057424Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.J Med Chem1982https://conductscience.org/library/papers/7057424PubMed
151592536Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.Int J Cancer1992https://conductscience.org/library/papers/1592536PubMed
168261429Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.Cancer Res1994https://conductscience.org/library/papers/8261429PubMed

Download CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
34399200Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.Biomed Pharmacother2021https://conductscience.org/library/papers/34399200PubMed
28123991Enhanced bioavailability of danazol nanosuspensions by wet milling and high-pressure homogenization.Int J Pharm Investig2016https://conductscience.org/library/papers/28123991PubMed
24459591Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems.ISRN Pharm2013https://conductscience.org/library/papers/24459591PubMed
23326192Self-microemulsifying drug-delivery system for improved oral bioavailability of pranlukast hemihydrate: preparation and evaluation.Int J Nanomedicine2013https://conductscience.org/library/papers/23326192PubMed
18852140Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.Mol Cancer Ther2008https://conductscience.org/library/papers/18852140PubMed
18473177Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization.AAPS PharmSciTech2008https://conductscience.org/library/papers/18473177PubMed
16323952Cross-linked polymeric nanogel formulations of 5'-triphosphates of nucleoside analogues: role of the cellular membrane in drug release.Mol Pharm2005https://conductscience.org/library/papers/16323952PubMed
15906174The influence of water content of triglyceride oils on the solubility of steroids.Pharm Res2005https://conductscience.org/library/papers/15906174PubMed
12162758Clinical pharmacokinetics of cytarabine formulations.Clin Pharmacokinet2002https://conductscience.org/library/papers/12162758PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8954169

GET https://conductscience.org/api/papers/v1/8954169/authors